Literature DB >> 32808205

Drug Removal Strategies in Competitive Ligand Binding Neutralizing Antibody (NAb) Assays: Highly Drug-Tolerant Methods and Interpreting Immunogenicity Data.

Michael A Partridge1, Elif Kabuloglu Karayusuf2, Gary Shyu2, Camille Georgaros2, Albert Torri2, Giane Sumner2.   

Abstract

Neutralizing anti-drug antibody (NAb) assays often have lower drug tolerance (DT) than trough drug concentrations, potentially under-estimating NAb incidence. To improve DT, drug-specific proteins were coupled to magnetic beads to deplete drug in the sample. To avoid interference from carryover, drug-specific proteins that did not interfere in the NAb assay, such as target or non-blocking anti-drug antibodies, were selected. With the drug depletion step, DT improved by > 10-fold in two competitive ligand binding NAb assays. Analysis of anti-drug antibody positive clinical samples with elevated drug levels demonstrated that NAb incidence was under-estimated without the drug depletion step. However, these NAb-positive samples had low titer and no impact on drug concentrations.

Keywords:  competitive ligand binding assays; drug depletion; drug tolerance; immunogenicity; neutralizing antibody

Mesh:

Substances:

Year:  2020        PMID: 32808205     DOI: 10.1208/s12248-020-00497-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  1 in total

1.  Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.

Authors:  Susan C Irvin; Amanda D'Orvilliers; Nicolin Bloch; Kayla Boccio; Jason Pennucci; Jurriaan Brouwer-Visser; Erica Ullman; Manoj Rajadhyaksha; Mohamed Hassanein; Terra Potocky; Albert Torri; Aynur Hermann; Michael A Partridge
Journal:  AAPS J       Date:  2022-06-21       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.